Medexus Announces US$58.5 million in New Credit Facilities
TORONTO and CHICAGO, March 08, 2023 (GLOBE NEWSWIRE) — Medexus Pharmaceuticals (TSX: MDP; TSX: MDP.DB; OTCQX: MEDXF) today entered into a new senior secured credit agreement agented by BMO. The credit agreement provides for a US$35 million term loan facility and a US$3.5 million revolving loan facility for working capital. The term loan facility benefits from an additional US$20 million uncommitted accordion feature, which Medexus is confident will be available. The new BMO facilities will mature in March 2026, being three years from the date of the credit agreement.
Related news for (MEDXF)
- Medexus to Participate in the 2023 Bloom Burton & Co. Healthcare Investor Conference
- Medexus Expects Record Revenue for Fiscal Year 2023 and Provides Business Update
- Medexus Announces New License Deal for Topical Terbinafine
- Medexus Announces Another Record Quarter with Fiscal Q3 2023 Revenue of US$28.7 Million, a 35% Increase Over Fiscal Q3 2022